期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 217, 期 1-2, 页码 28-37出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2009.08.017
关键词
EAE; Hsp70; Inflammation; NF-kappa B; Oral; Triptolide
Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. in this study, we examined the immunomodulatory properties of orally administered triptolide, a major diterpenoid triepoxide isolated from a twining vine Tripterygium wilfordii. SJL/J mice were primed with PLP(139-151) peptide and orally treated with triptolide (100 mu g/kg per day) from the day of EAE induction (preventive regime) and after the onset of clinical signs (therapeutic regime). Triptolide delayed disease onset, reduced clinical symptoms, decreased the relapse rate, and suppressed inflammation and demyelination in CNS tissue of EAE mice when compared to vehicle-treated animals. Molecular analysis revealed a marked increase of heat shock protein 70 (Hsp70) mRNA and protein in the CNS tissue of triptolide-treated animals. Cytokine and chemokine expression analysis from EAE tissues and in vitro macrophages detected a decrease of key pro-inflammatory mRNAs. Triptolide inhibited I kappa B alpha phosphorylation and NF-kappa B nuclear translocation by stabilization of NF-kappa B/I kappa B alpha complex, possibly due to a direct physical interaction between NF-kappa B and Hsp70 proteins. Lymph node cell proliferation assay in EAE confirmed the immunosuppressive efficacy of triptolide. Our data indicate that daily oral administration of triptolide exhibits not only a preventive but also a therapeutic effect on EAE. These effects might be explained by the increase in Hsp70 levels driven by triptolide and stabilization of the NF-kappa B/I kappa B alpha complex leading to an attenuated inflammatory response. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据